LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Fechado

1.13 -0.88

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.12

Máximo

1.15

Indicadores-chave
By Trading Economics
Rendimento	3.5M -20M
EPS	-0.32
Funcionários	49
EBITDA	6.8M -22M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+132.17% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	6.7K 74M
Abertura anterior	2.01
Fecho anterior	1.13

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de jun. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 de jun. de 2026, 15:41 UTC

Grandes Movimentos do Mercado

American Battery Shares Jump on Energy Department Victory

8 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 de jun. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Agrees to Buy m3ter

8 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

8 de jun. de 2026, 19:22 UTC

Conversa de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 de jun. de 2026, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 de jun. de 2026, 18:17 UTC

Conversa de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 de jun. de 2026, 17:32 UTC

Conversa de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de jun. de 2026, 16:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 de jun. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 de jun. de 2026, 16:40 UTC

Conversa de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 16:31 UTC

Conversa de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 de jun. de 2026, 16:27 UTC

Conversa de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de jun. de 2026, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Bought Stake From Lorca

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Acquires 100% Ownership of MasOrange

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 15:55 UTC

Conversa de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 de jun. de 2026, 15:41 UTC

Conversa de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

132.17% parte superior

Previsão para 12 meses

Média 2.67 USD 132.17%

Máximo 3 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.